<PAGE>

                                                                  EXHIBIT 10(jj)


* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.  ASTERISKS DENOTE OMISSIONS.

                        CONTRACT MANUFACTURING AGREEMENT
                        --------------------------------

      This Agreement, dated this 10th day of April 2001, for reference only, is
by and between Kensey Nash Corporation, a Delaware Corporation, located at 55
East Uwchlan Avenue, Exton, PA 19341 (hereinafter "Supplier"), and
Organogenesis Inc., a Delaware Corporation, located at 150 Dan Road, Canton, MA
 02021 (hereinafter "Buyer").

     WHEREAS, Supplier possesses technology, trade secrets, and patents related
to medical and or surgical apparatus, systems, procedures, devices and
components such as, but not limited to, biomaterial products for drug and
growth factor delivery, puncture closure devices, absorbable fixation devices,
vascular grafts, anastomosis and angiogenesis; and

     WHEREAS, Buyer possesses technology, trade secrets, and patents related to
medical and or surgical apparatus, systems, procedures, devices and components
such as, but not limited to, biomaterial products derived from mammalian
intestinal collagen that it has disclosed and transferred to Supplier; and

     WHEREAS, Buyer has paid and will continue to pay Supplier for the
development costs of processes and equipment necessary and desirable for the
scale-up of the manufacture and exclusive supply to Buyer of certain products;
and

     WHEREAS, Buyer and Supplier jointly, and both parties separately have and
will continue to conceive and reduce to practice valuable proprietary
intellectual property, whether or not patentable, used or useful in the
scale-up of the manufacture and supply of certain products by Supplier to Buyer
for which Buyer will have paid Supplier; and

     WHEREAS, Buyer desires to purchase its requirements of certain products
from Supplier; and

     WHEREAS, Supplier desires to sell certain products exclusively to Buyer
under the terms and conditions set forth herein;

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants and agreements provided herein, the parties hereto, intending to be
legally bound hereby, agree as follows:

1.   PRODUCT: Supplier shall manufacture and sell Product exclusively to Buyer
     --------
     throughout the Term, where "Product" means any article containing a
     natural acellular biomaterial derived from mammalian intestinal collagen
     that is manufactured by Kensey Nash and is intended for any use as a
     healthcare product.  All Product shall meet the "Specifications" set forth
     in Schedule A, and the requirements of Schedule C ("Drawing"), which are
     attached hereto and made a part of this Agreement.  Such Specifications
     may be changed from time to time only as agreed to in writing by the

                                  Page 1 of 17

<PAGE>


* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.  ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  --------------------------------

     parties, additionally, said changes being subject to the requirements of
     Articles 7 and 21 herein.

2.   DURATION:  The duration of this Agreement shall be from the Effective Date
     ---------
     and continue until January 1, 2005, unless otherwise agreed in writing by
     the parties (the "Term"); where "Effective Date" is the date of the last
     executing signature hereon, which signifies the start of the Agreement
     Term.  This Agreement shall be automatically renewed for successive one
     (1) year terms thereafter unless either party notifies the other party to
     the contrary not less than 180 days prior to the expiration of the then
     current term.

3.   FORECAST QUANTITIES:  Subject only to other provisions of this Agreement,
     --------------------
     Supplier shall sell exclusively to Buyer and Buyer shall purchase from
     Supplier one-hundred percent (100%) of Buyer's requirements for Product or
     substantially equivalent products.  Throughout the Term Buyer shall
     provide Supplier with a rolling four-quarter forecast of its estimate of
     its demand for Product within 30 days of the beginning of each calendar
     quarter for the next four quarters.  Buyer's forecast for the first such
     subsequent quarter of each such rolling forecast shall be binding on both
     Buyer and Supplier, following the second full quarter of any product's
     commercial introduction to the market.  Supplier shall advise Buyer within
     ten business days of receipt of each such forecast if the forecasted
     requirements are expected to exceed Supplier's ability to supply.  During
     the initial year of this Agreement, Buyer agrees to supply a forecast to
     Supplier covering the forecasted requirements for the balance of the
     current calendar year, such forecast to be supplied within thirty (30)
     days of the signing of this Agreement, or within thirty (30) days of the
     placement of the first Product order, whichever occurs later.

4.   INCREASED QUANTITIES:  During the Term, Supplier will supply in any given
     ---------------------
     year up to two-hundred percent (200%) of the expected annual purchase
     quantities indicated in Buyer's annual forecast without further Agreement.
     In the event that Buyer requires in any year quantities which exceed
     two-hundred percent (200%) of the forecasted annual quantity, Buyer shall
     so notify Supplier in writing at least as many days in advance of Buyer's
     desired shipping date as there are days in one complete production cycle
     for Products.  Supplier shall use its reasonable efforts (consistent with
     good business practice) to meet Buyer's requirements for such additional
     Product and shall inform Buyer within thirty (30) days of notice whether
     or not Supplier will supply all or a portion of such requirements.

5.   REDUCED QUANTITIES: During the term of this Agreement, Buyer may order in
     -------------------
     any given year a quantity down to [***] of the expected annual purchase
     quantities indicated in Buyer's rolling forecast for any product or
     Products without further agreement. In the event that Buyer does not order
     at least [***] of the annually forecasted requirements for any Product,
     Buyer will pay an inventory fee, not to exceed five percent (5%) of the
     difference in price between [***]of the annual forecast and the amount of
     that product actually ordered.  The order shortfall shall be

                                  Page 2 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.  ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  --------------------------------

     determined by calculating the amount that the actual annual order total
     falls below [***] of the forecast.  The inventory fee for any Product will
     be waived, so long as orders for Product remain above [***] of forecast of
     Products.  In addition, Buyer shall reimburse Supplier for finished
     Product ("Inventory") that has exceeded its shelf-life in any quarter
     where orders fall below [***] of quarterly estimates of said forecast
     ("Reimbursement"). At the request of Buyer, Supplier will purchase from
     ICG or another mutually acceptable raw material supplier, and store at a
     mutually satisfactory location having suitable environmental controls such
     as refrigeration, up to a one-year inventory of chemically cleaned porcine
     intestinal material, and will refresh such stored inventory frequently
     enough to assure that it is continually in-dated.  Buyer will pay for such
     inventory at its cost to Supplier plus Supplier's cost of storage and
     handling, which in the aggregate are hereby established at fifteen percent
     (15%) of Supplier's cost of inventory of mechanically cleaned porcine
     intestinal material, and Buyer will thereafter receive from Supplier a
     credit equal to the "cost to Supplier", said credit to be applied to
     Buyer's orders as stored inventory is used to manufacture Product.

6.   ORDER AND DELIVERY: Buyer shall issue a purchase order for each delivery
     -------------------
     of Product under this Agreement.  Each purchase order shall state the
     desired shipment date and the quantity being ordered. Supplier shall
     acknowledge promptly each purchase order issued by Buyer in writing, shall
     in any case notify Buyer within 10 business days of its discovery of its
     inability to timely deliver any Product ordered by each purchase order,
     and shall confirm delivery dates to destinations specified by Buyer;
     however, delivery dates must not conflict with Supplier's customary
     manufacturing lead times, although premium pricing may be enacted to
     accelerate delivery where Supplier's normal scheduling is in conflict with
     Buyer's requirements.  Supplier will ship Product ordered by Buyer
     promptly upon completion of its manufacture.  Each delivery of Product
     shall be accompanied by Supplier's Certificate of Conformance.

7.   PRICE: Subject to the requirements in Article 9 governing continual
     ------
     product improvement, the initial price for the Product is listed in
     Schedule B ("Price"), which is attached to this Agreement and made a part
     hereof. The price in Schedule B will remain in effect for the first 12
     months of the Term.  The Price may be adjusted by Supplier semiannually
     thereafter by so notifying Buyer in writing at least sixty (60) days prior
     to the effective date of such change and shall be adjusted semiannually
     throughout the Term to reflect any Improvements, as hereinafter defined.
     Pricing may be changed for other factors such as, but not limited to,
     revisions to specifications, revisions to lot release criteria, raw
     material costs, regulatory costs, or increases in product liability costs
     provided that any such revisions or costs are related solely to Product.
     No cumulative price increase (but not any price decrease) may exceed on a
     percentile basis the greater of the cumulative increase in either the CPPI
     (i.e., Producers Price Index for Chemicals and Allied Products, as
     published by the United States Department of Labor, Bureau of Labor
     Statistics) or the CPI (Consumer Price Index) between the Effective Date
     of this Agreement, or as applicable, the date of the

                                  Page 3 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.  ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  --------------------------------

     last Price increase, and the date of the proposed price increase. Buyer
     may accept such price increase, renegotiate this Agreement, or elect to
     terminate this Agreement; however, Buyer may not terminate if said
     increase is solely due to Buyer's actions.  If Buyer elects to renegotiate
     this Agreement according to the terms of this Article, Supplier agrees to
     continue to provide Buyer with Product hereunder at the then current
     contract price for ninety (90) days. If Buyer elects to terminate this
     Agreement according to the terms of this Article, Supplier will continue
     to provide Buyer with product hereunder at the current contract price for
     180 days, but Supplier may opt to continue supplying Product during the
     balance of the first twelve months of this Agreement, if the first twelve
     months have not been completed. During the Term, Buyer will be invoiced at
     the Price corresponding to the Buyer's forecasted annual requirements;
     adjustments, both refunds and additional charges, will be made within
     sixty (60) days of the close of each year should Buyer's actual purchases
     differ from the forecasted annual quantities.  Supplier's cost for
     Inventory shall include Price and storage costs incurred by Supplier
     ("Inventory Cost"). Reimbursement under Article 5 of this Agreement shall
     be based upon this Inventory Cost.

8.   BUSINESS INTERRUPTION:  Supplier shall notify Buyer at the earliest
     ----------------------
     practicable time of any circumstance that would prompt any reasonable
     seller to conclude that any delivery of Products would not be made in
     conformity with the terms of this Agreement or any purchase order (each, a
     "Failure").  Both parties will use their best efforts to reduce or
     eliminate any Failure in the shortest possible time.  If either party
     concludes that the other is not using its best efforts to reduce or
     eliminate any Failure, then that party may commence binding arbitration as
     described in Article 40.  If any Failure occurs during the Term and
     continues for a period greater than the number of days in one complete
     production cycle or ninety (90) days, whichever is greater, for any
     Product affected by the Failure, then Supplier shall cooperate with Buyer
     to promptly and efficiently disclose to Buyer or its designee, and will
     permit Buyer or its designee to use at Supplier's expense, all
     information, processes and techniques known or possessed by Supplier that
     are necessary or convenient for the efficient manufacture of any Product
     affected by any Failure, including disclosing any necessary portion of
     Supplier's device master record for that Product (such information,
     processes, and techniques being "Procedures").  However, no Failure shall
     be deemed to occur within the first year following the Effective Date.
     Supplier's expense, as used in this paragraph, shall be limited to the
     cost of transportation of said device master record and a reasonable
     training period regarding Procedures contained therein.  The right of
     Buyer or its designee to use any Procedures shall extend only for the
     period required for Buyer to both obtain a commercially reasonable
     third-party source of supply, and for Supplier to demonstrate to the
     reasonable acceptability of Buyer Supplier's renewed ability to supply
     Product according to the terms of this Agreement and any purchase order.
     Any use of procedures by Buyer, its designee, or third-party supplier,
     pursuant to this Article, shall be under terms of confidentiality at least
     as restrictive as those existing between Buyer and Supplier including
     those referenced in Article 33 of this Agreement.  Where feasible,
     disclosure of procedures will be from Supplier to designee or third-party,
     as appropriate.

                                  Page 4 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.  ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  --------------------------------


9.   CONTINUAL PRODUCT IMPROVEMENT:  The parties agree to work jointly and
     ------------------------------
     separately throughout the Term to improve Products and the methods of
     their manufacture, including but not limited to redesigns and improvements
     that reduce the price of Products ("Improvements").  Each party shall
     promptly disclose to the other the nature of any Improvements, whether or
     not patentable, made during the Term by either party.  The cost of
     patenting any Improvement made solely by one party shall be borne solely
     by it, and the cost of patenting any joint Improvement shall be borne
     equally by both parties.  The parties hereto shall incorporate
     Improvements deemed beneficial by either party into the manufacture of
     Products, and a subsequent Price for that Product shall be negotiated in
     good faith between the parties.

10.  TERMINATION: Either party may terminate this Agreement in the event that
     ------------
     the other party materially breaches or defaults in the performance of any
     material obligation, and such breach or default continues for sixty (60)
     days after written notice thereof to the other in accordance with the
     provisions hereof governing notice.  No Failure, in and of itself, shall
     be cause for termination.  Any termination shall be effective at the end
     of that notice period unless the breaching or defaulting party cures its
     breach or default within the 60-day notice period.  If voluntary or
     involuntary proceedings by or against a party are instituted in bankruptcy
     under any insolvency law, or a receiver or custodian is appointed for such
     party for corporate reorganization or for the dissolution of such party,
     which proceedings, if involuntary, shall not have been dismissed within
     sixty (60) days after the date of filing, or if such party makes an
     assignment for the benefit of creditors, or substantially all of the
     assets of such party are seized or attached and are not thereafter
     released within sixty (60) days, the other party may terminate this
     Agreement forthwith by notice in accordance with the provisions governing
     notice.  In the event of any termination or expiration of this Agreement,
     Buyer may use and disclose Procedures, subject to Article 27 herein, and
     purchase, free of any lien, any or all capital equipment purchased by
     Supplier specifically for the manufacture or storage of Product, at its
     then depreciated cost to Supplier.  Said capital equipment being specified
     pursuant to the Phase II development program described in Article 11.

11.  PREPRODUCTION PHASE: Supplier represents that it will timely complete the
     --------------------
     undertakings it has made in the "Phase II" development program at the
     prices described in the letter to Buyer from Supplier dated January 19,
     2001, and attached hereto.

12.  WARRANTY: Supplier warrants that the Product shipped hereunder meets the
     ---------
     Specifications set forth in Schedule A, and that said Product is free from
     any liens.  Other than the foregoing, SUPPLIER MAKES NO WARRANTIES,
     EXPRESS OR IMPLIED, OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR
     PURPOSE EVEN WHERE THE USE OR PURPOSE IS KNOWN TO SUPPLIER.  Buyer assumes
     all risk and liability for results obtained by the use of Product covered
     by this Agreement, whether used singly or in

                                  Page 5 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                 CONTRACT MANUFACTURING AGREEMENT (continued)
                 ---------------------------------

     combination with other products. SUPPLIER SHALL NOT BE LIABLE TO BUYER OR
     ANY OTHER AGENT OR REPRESENTATIVE THEREOF FOR ANY LOSS OF PROFITS, LOSS OF
     BUSINESS OR INTERRUPTION OF BUSINESS, OR FROM ANY INDIRECT, SPECIAL OR
     CONSEQUENTIAL DAMAGES OF ANY KIND INCURRED BY OR ANY OTHER AGENT OR
     REPRESENTATIVE THEREOF, UNDER THIS AGREEMENT OR OTHERWISE.

13.  INDEMNIFICATION: Buyer shall fully indemnify, defend and hold harmless
     ---------------
     Supplier against all loss and expense, including, but not limited to,
     court costs, expenses, and reasonable attorney's fees, resulting from
     injury to or death of any person, loss of or damage to property, or
     intellectual property claims, so long as loss results in any way from
     Buyer's use or sale of Product, or any act or omission, negligent or
     otherwise, on the part of the Buyer, its agents, employees, subcontractors
     or assignees, in connection with Supplier's  performance of this
     Agreement, except when any loss or expense is caused by the misconduct or
     negligence of Supplier.

14.  USE OF TRADEMARK: Each party agrees that it will not, without the other
     ----------------
     party's prior written consent, use and/or associate the other party, the
     other party's corporate name or any of the other party's trademarks,
     either orally or in writing, with any of the other party's products,
     except that Buyer may use Supplier's name and associate Supplier with
     Buyer's Product as is required by federal or state regulation in gaining
     approval to market or to continue marketing Buyer's Product.

15.  CLAIMS: Buyer shall provide notice to Supplier of any claim arising from
     ------
     the Product within forty-five (45) days after receipt of each shipment.
     Failure to give notice of claim within forty-five (45) days from the date
     of delivery, or the date fixed for shipment in the case of nondelivery,
     shall constitute a waiver by Buyer of all claims with respect to such
     Product, so long as reasonable inspection, including any agreed to
     incoming inspection, would have revealed claim.  No claim shall be allowed
     after Product has been processed by Buyer in any manner. Upon Supplier's
     confirmation, Supplier will provide Buyer with credit, refund or
     replacement, at Supplier's discretion, for the shipment containing the
     non-conforming Product. Product shall not be returned to Supplier without
     Supplier's prior permission, and then only in the manner and to the
     destination prescribed by Supplier.  Supplier shall reimburse Buyer for
     the actual costs of returning any Product returned in accordance with
     Supplier's instructions. In no event shall Supplier be liable to Buyer for
     special, indirect or consequential damages.

16.  QUALITY CONTROL: All Products shall meet the specifications contained in
     ---------------
     Schedule A, subject to Supplier's standard and lawful non-conformance or
     deviation procedures, and shall be subjected to quality control
     inspections by Supplier in accordance with Supplier's quality control
     standards and system.  If Buyer's inspection shows that the Product fails
     to meet the specifications contained in Schedule A, Buyer shall notify
     Supplier within forty-five (45) days of receipt of the non-conforming

                                  Page 6 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                 CONTRACT MANUFACTURING AGREEMENT (continued)
                 ---------------------------------

     Product, provided that reasonable inspection would have revealed the
     failure.  Promptly after the Effective Date the quality assurance
     representatives of the parties shall confer to agree upon the most
     efficient assignment of quality and variance reporting functions between
     them.

17.  TERMS OF PAYMENT:  Buyer will pay to Supplier the invoiced amount paid net
     ----------------
     cash forty-five (45) days from date of Supplier's invoice.  Supplier may
     impose a late payment service charge of 1.5% per month on invoices not
     paid when due.  All payments shall be in United States currency.

18.  FINANCIAL RESPONSIBILITY: In the event Buyer fails to fulfill the terms of
     ------------------------
     payment, or in case Supplier shall have a substantial doubt at any time as
     to Buyer's financial responsibility, Supplier may decline to make further
     deliveries except upon receipt of cash or satisfactory security.

19.  RISK OF LOSS: Deliveries shall be F.O.B. Exton, Pennsylvania, USA via
     ------------
     standard, freight carrier.  Buyer shall be responsible for any and all
     product damage or loss from using a non-refrigerated carrier (unless
     agreed upon insulated shipping method is used).  Buyer shall be
     responsible for all delivery costs and will be invoiced for such by
     Supplier.  Title to and risk of loss in all Product sold hereunder shall
     pass to Buyer upon loading for shipment at Supplier's plant.

20.  FORCE MAJEURE: No liability shall result from delay in performance, or
     -------------
     nonperformance, caused by circumstances beyond the control of Supplier,
     including, but not limited to, acts of God, fire, flood, war, Government
     action, accident, labor trouble or shortage, inability to obtain material,
     utilities, equipment or transportation.  Quantities so affected may be
     eliminated from the Agreement without liability, but the Agreement shall
     remain otherwise unaffected. Should acts of God, fire, flood, war,
     Government action, accident, labor trouble or shortage, utilities,
     equipment or transportation, prevent Buyer from performing Buyer's
     obligations under this Agreement for a continuous period of six (6)
     months, Buyer may cancel the balance of the Agreement.  Upon claiming the
     benefit of this section, the party claiming the benefit shall promptly so
     notify the other party and the reasons therefor, and claiming party shall
     use its reasonable efforts, consistent with good business practices, to
     minimize such delays.

21.  REGULATORY RESPONSIBILITIES: Supplier shall manufacture Product under this
     ---------------------------
     Agreement in material compliance with the U.S. Quality System Regulation
     (QSR) and ISO 9001/EN 46001 in accordance with the Supplier's protocols.
     Any changes to the Specifications or Drawings relating to the final
     product must be agreed to in writing by both parties before such changes
     are implemented. Buyer shall be responsible for obtaining all necessary
     government approvals to market Buyer's application.  Buyer shall pay for
     those sterilization validations that are required for the commercial
     manufacture of finished Product, subject to separate negotiation with
     Supplier regarding the price and extent thereof, or alternatively Buyer
     may perform

                                  Page 7 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                 CONTRACT MANUFACTURING AGREEMENT (continued)
                 ---------------------------------

     them internally or have them performed by a third party.
     Buyer shall indicate Buyer's validation preference in writing prior to the
     shipment by Supplier of production quantities of Product.  Upon terms of
     confidentiality reasonably acceptable to Supplier, Supplier agrees to
     provide reasonable assistance to Buyer in obtaining any such governmental
     approvals, including providing required information to the U.S. Food and
     Drug Administration or any other governmental agency requesting the
     information to the extent such information is readily available or can be
     developed at minimal cost to Supplier; alternatively Buyer agrees to fund
     such information development and preparation.  Confidential disclosures
     will be made by Supplier directly to the third-party agency, on behalf of
     Buyer; Buyer's direct access to data will remain limited to reports
     customarily provided by Supplier.

22.  REGULATORY SUPPORT: Assurance of continuing compliance with regulatory
     ------------------
     requirements issued following the shipment of Product is to be considered
     "Regulatory Consulting", and is not a requirement under this Agreement. If
     Regulatory Consulting or ongoing access to Supplier's material database is
     required, Supplier will invoice Buyer separately for this service(s). If
     Buyer agrees to fund such consulting, Supplier will charge Buyer its
     "preferred" consulting rate, said preferred rate being discounted fifteen
     percent (15%) below Supplier's standard consulting rate.

23.  ADVERSE EVENT REPORTING: Each party hereto agrees to report promptly to
     -----------------------
     the other party any information concerning serious or unexpected side
     effects, injury, toxicity, reactions or any unexpected event associated
     with clinical, investigational or commercial use of Product. Such
     information shall also include, to the extent known, pre-existing
     diseases, syndromes, or abnormal diagnostic tests results that re-appear
     or are exacerbated by use of Product.  Statements of customer
     dissatisfaction not related to such serious or unexpected effects will be
     the sole responsibility of Buyer; Supplier will notify Buyer promptly of
     such statements of which it receives information, and Buyer may but is not
     required to notify Supplier of them.  Upon receipt of such information by
     either party hereto, both parties shall promptly consult each other and
     use best efforts to arrive at a mutually acceptable procedure for taking
     the appropriate actions under the circumstances; provided, however, that
     nothing contained herein shall restrict the right of either party to make
     a submission to a regulatory authority or take other actions it deems to
     be appropriate or necessary.  As between the parties Buyer shall be
     responsible for all medical device reporting (MDR), vigilance reporting,
     and recalls, associated with Buyer's application, which incorporates
     Product. Supplier shall be notified in writing of any such reports or
     recalls.

24.  COMPLIANCE WITH LAW: Each party represents that it is and will remain in
     -------------------
     material compliance with all applicable federal, state and local laws,
     regulations and orders.

25.  INDEPENDENT CONTRACTOR: The employees, methods, equipment and facilities
     ----------------------
     of each party shall at all times be under that party's exclusive direction
     and control.

                                  Page 8 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                 CONTRACT MANUFACTURING AGREEMENT (continued)
                 ---------------------------------

     Buyer's relationship to Supplier under this Agreement shall
     be that of an independent contractor and nothing in this Agreement shall
     be construed to constitute either party, or any of its employees, an
     agent, associate, joint  venturer or partner of the other party.

26.  INTELLECTUAL PROPERTY: The parties acknowledge that each owns or has
     ---------------------
     rights to commercially valuable intellectual property, whether or not
     patented, conceived and developed by each of them independently prior to
     July 17, 2000, the date of the confidentiality agreement between the
     parties.  All such intellectual property or rights shall be and remain the
     sole property of the party owning or having rights to that intellectual
     property.  Supplier acknowledges that since July 17, 2000 and continuing
     throughout the Term Buyer will continue to disclose its valuable
     intellectual property to Supplier to enable it to manufacture and sell
     Product efficiently to Buyer, and that since July 17, 2000 the parties
     have jointly and Supplier has solely conceived additional commercially
     valuable intellectual property, whether or not patentable, related to the
     scale-up of manufacture of Product, which may include intellectual
     property conceived or developed by Buyer prior to July 17, 2000, the costs
     of which have been borne by Buyer (all such intellectual property
     hereafter being referred to collectively as the "After-acquired
     Intellectual Property").  Except as provided in Article 27, all
     After-acquired Intellectual Property shall be and remain the sole property
     of Buyer, will not be used or disclosed by Supplier except as is required
     to enable Supplier to fulfill its obligations hereunder, and Supplier will
     promptly disclose to Buyer all such After-acquired Intellectual Property
     conceived by it, and will execute any document necessary or convenient to
     confirm Buyer's ownership of After-acquired Intellectual Property or to
     obtain legal protection therefor.

27.  ROYALTY-FREE PERPETUAL LICENSE: Notwithstanding the previous Article, and
     ------------------------------
     subject to the restrictions in this Article, Buyer hereby grants to
     Supplier a royalty-free, paid up, perpetual license to make, use and sell,
     but not to disclose or sublicense to others, all After-acquired
     Intellectual Property conceived solely by Supplier.  Buyer may temporarily
     revoke this license with respect to all or any part of such After-acquired
     Intellectual Property if a Failure occurs as described in Article 8, or
     permanently revoke this license upon any termination of this Agreement.
     Buyer shall pay Supplier upon revocation or expiration an amount equal to
     the then-present value of the actual cost to Supplier of its conception
     and development of all that After-acquired Intellectual Property to which
     the revocation, or expiration applies, unless such termination is due to
     the fault of the Supplier, in which case no such payment shall be due.

28.  RIGHT OF BUYER TO LICENSE CERTAIN INTELLECTUAL PROPERTY:  Subject to the
     --------------------------------------------------------
     provision in the last sentence of this Article, Supplier may from time to
     time during the Term develop new product concepts or prototypes that
     incorporate mammalian intestinal collagen, but which are not manufactured
     for Buyer under this Agreement.  Should this occur, Supplier will notify
     Buyer and the parties will make a good faith effort to evaluate and, if
     appropriate, develop and commercialize resulting

                                  Page 9 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                 CONTRACT MANUFACTURING AGREEMENT (continued)
                 ---------------------------------

     products. If Buyer does not wish to participate in the development or
     commercialization of the new product, or the parties are not able to agree
     on the terms therefor within 90 days of Supplier's original offer,
     Supplier may thereafter license its intellectual property, and the right
     to manufacture that product, to a third entity.  Supplier may also use
     that intellectual property itself only so long as it is not used by
     Supplier to manufacture Products for another entity.  Provided, that, the
     right of Supplier to use or license such intellectual property shall not
     in any case apply to any After-acquired Intellectual Property described in
     Article 26.


29.  NOTICES: All notices required hereunder shall be in writing, and shall be
     --------
     sent by certified mail return receipt requested, or by facsimile confirmed
     by such certified mail, to the party to be notified at its following
     address or at such other address as shall have been specified in written
     notice from the party to be notified.  If to "Supplier", addressed to:
     Kensey Nash Corporation, 55 East Uwchlan Avenue, Exton, PA  19341,
     Attention: Joseph W. Kaufmann.  If to "Buyer", addressed to:
     Organogenesis, Inc, 150 Dan Road, Canton, MA  02021, Attention: Patrick
     Bilbo.

30.  ASSIGNMENT: This Agreement is not assignable or transferable by either
     -----------
     party hereto, in whole or in part, without the prior written consent of
     the other party. Such consent may not be unreasonably withheld.
     Notwithstanding the preceding prohibition, the sale or change of control
     of a party's corporate entity would allow the transfer of this Agreement
     to that party's successor in interest without approval from the other
     party.

31.  EXCLUSIVITY: Notwithstanding Article 3 herein, no relationship between
     ------------
     Buyer and Supplier, other than that of normal transactional buyer and
     seller, are created by this Agreement, unless expressly detailed and
     described herein.  Supplier shall not sell Product, as denoted and
     described in Article 1 or Schedule A of this Agreement, to parties other
     than Buyer.

32.  CLAUSE HEADINGS: The headings of clauses contained herein are used for
     ----------------
     convenience and ease of reference and shall not limit the scope or intent
     of the clause.

33.  DOCUMENTS INCORPORATED BY REFERENCE: The following documents are hereby
     ------------------------------------
     incorporated by reference:

       Schedule A entitled "Product Specifications", attached hereto;
       Schedule B entitled "Pricing " dated February 5, 2001, and attached
            hereto;
       Schedule C entitled "Drawing", attached hereto;
       Phase II Proposal (Revised) between the parties dated January 19, 2001,
            and attached hereto.

34.  ENTIRETY OF AGREEMENT: This Agreement embodies the entire agreement and
     ----------------------
     understanding between Supplier and Buyer relative to the subject matter
     hereof;

                                  Page 10 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  ---------------------------------

     however the parties to this Agreement deem the non-disclosure agreement
     ("NDA"), separately executed and dated July 17th, 2000, to be of a
     general business nature and therefore declare the NDA to be and remain in
     full force and effect.

35.  CONFLICT OF TERMS: Any non-standard, preprinted term of any document
     ------------------
     (including those typically found at the end or on the reverse of any such
     document), including but not limited to a purchase order or acceptance,
     sent to either party by the other in connection with either's performance
     under this Agreement, shall be null, void and of no effect.

36.  MODIFICATION OF AGREEMENT: No amendment, modification or release from
     --------------------------
     any provision hereof shall be of any force or effect unless it is in
     writing, signed by the party claimed to be bound thereby, and
     specifically refers to this Agreement.

37.  WAIVER: No waiver by either party of any breach of the covenants
     -------
     herein contained to be performed by the other party shall be construed as
     a waiver of any succeeding breach of the same or any other covenants or
     conditions herein.

38.  GOVERNING LAW: This Agreement shall be governed by and interpreted in
     --------------
     accordance with the laws of the Commonwealth of Pennsylvania, and shall
     be deemed to have been made and executed therein.

39.  SURVIVAL OF PROVISIONS: The obligations of the parties undertaken
     -----------------------
     pursuant to Articles 12,13,14,15,16,21,23,26,27 and 37 of this Agreement
     and the definition of any term used in any of those Articles shall
     survive the termination of this Agreement.

40.  BINDING ARBITRATION: The parties agree to attempt to settle any
     --------------------
     dispute under this Agreement by mutual discussion and consent. Any
     dispute between the parties not resolved by amicable discussions shall be
     settled by binding arbitration, which may be commenced by notice from
     either party to the other at any time during the Term pursuant to the
     provisions hereof governing notice (the "Commencement Notice"). Any such
     notice shall contain a short, clear statement of the nature of the
     dispute (the "Statement"). The party receiving the notice may, but is not
     required to, reply to the notice promptly with its own Statement. Within
     10 days of receipt of any Commencement Notice each party, pursuant to the
     provisions hereof governing notice, shall advise the other of the name,
     address, affiliation, and phone number of one individual, not an
     employee, director or agent of that party, or a relative of any of the
     foregoing. The two individuals so appointed shall appoint within 10 days
     thereafter a third individual who shall be a person with generally
     recognized competence in the field of the manufacture, marketing and sale
     of biomaterials for healthcare use. The three individuals so appointed
     (the "Arbitrator(s)") shall receive and consider any relevant information
     provided to them by either party, either orally or in writing, if, but
     only if, the information is provided to each of the three individuals
     both within 10 days of the date of the appointment of the third
     Arbitrator and is either accompanied by the sworn affidavit of an officer
     of the submitting party

                                  Page 11 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  ---------------------------------

     attesting to its accuracy and completeness, or is given under oath (all
     such information hereafter "Evidence"). The Arbitrators shall, by a
     majority vote taken within 10 days of the receipt of all Evidence, render
     a written judgment based solely upon the Evidence that is the narrowest
     reasonable award dispositive of the dispute contained in the Statements.
     Any arbitration commenced by one party against the other shall take place
     in the jurisdiction of the other, excluding cross-actions. The costs of
     the arbitration, including administrative and the Arbitrators' fees,
     shall be shared equally by the parties. Each party shall bear its own
     costs and attorneys' and witnesses' fees. Neither party shall commence
     any action in any court to resolve any dispute between them except to
     confirm any such arbitration award. Commencement of any such action shall
     be a breach of this Agreement entitling the other, in addition to any
     other remedy it may have at law or in equity, to terminate this Agreement
     forthwith.


Accepted by the following authorized individuals:

Kensey Nash Corporation                Organogenesis Inc.

By:                                    By:
/s/ Joseph W. Kaufman                  /s/ Paul J. DiCicco
----------------------------------     ------------------------------

Print:                                 Print:
          Joseph W. Kaufmann           Paul J. DiCicco
                                       ------------------------------

Title:   President and CEO             Title:
                                       Vice President, Operations
                                       ------------------------------

Date:                                  Date:
4/10/01                                4/12/01
----------------------------------     ------------------------------

                                  Page 12 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  ---------------------------------


SCHEDULE A-PRODUCT SPECIFICATIONS
---------------------------------


The parties will mutually agree to, and will attach, Specifications as soon as
reasonably practicable.
Date: [insert date]

                                  Page 13 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  ---------------------------------


SCHEDULE B--PRICING
------------------


Engineered Collagen Matrix Products - Individually Final Packaged and Gamma
---------------------------------------------------------------------------
Sterilized
----------

-------------------------------------------------------------------------------
                                 Annual Order Quantity
-------------------------------------------------------------------------------

Piece Pricing                    ********   ***********   **********
-------------------------------------------------------------------------------
Wound Dressing (single layer):   ********   ********      *********
     5cm [multiply] 5cm
-------------------------------------------------------------------------------
     10cm [multiply] 10cm        ********   ********      *********
-------------------------------------------------------------------------------
Surgical Patch (5 layers):       ********   ********      *********
     5cm [multiply] 10cm
-------------------------------------------------------------------------------
     10cm [multiply] 15cm        ********   ********      *********
-------------------------------------------------------------------------------
Urogyn Sling (5 layers):         ********   ********      *********
     2cm [multiply] 10cm
-------------------------------------------------------------------------------
     2cm [multiply] 30cm         ********   ********      *********
-------------------------------------------------------------------------------
Dura Patch (4 layers):
     5cm [multiply] 5cm          ********   ********      *********
-------------------------------------------------------------------------------
     10cm [multiply] 10cm        ********   ********      *********
-------------------------------------------------------------------------------

Date: February 5, 2001

                                  Page 14 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  ---------------------------------

SCHEDULE C--DRAWING
-------------------

The parties will agree to and will attach a drawing suitable for Supplier's
quality system as soon as reasonably proacticable.


Date: [insert date]

                                  Page 15 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  ---------------------------------

                      COPY OF PHASE II PROPOSAL (REVISED)
                      -----------------------------------

January 19, 2001

                                                                         REVISED
Mr. Patrick Bilbo                                                        -------
Organogenesis, Inc.
150 Dan Road
Canton, MA  02021

Dear Patrick:

Thank you for this opportunity to continue to work with Organogenesis on your
Engineered Collagen Matrix (ECM) product. Per our previous conversations, we
are happy to quote on Phase 2 development of the commercial manufacturing
process for this product. Based upon our previous review of the information you
have provided as well as ongoing discussions, we have prepared a detailed
analysis of the tasks required in order to provide you with commercial quality
ECM product manufactured by Kensey Nash. We are confident we can provide you
with product that meets your specifications.

We will use the information gathered during the process development phase
(Phase 1) in order to more accurately define the full scale manufacturing
process to successfully complete the commercial production phase (Phase 2). We
will describe below the tasks necessary and the various assumptions made for
Phase 2 of the project.

COMMERCIAL PRODUCTION PHASE -- PHASE 2
--------------------------------------
Based upon information obtained during Phase 1, we will develop the full-scale
manufacturing process for the ECM product in four configurations (unlaminated
single layer [Wound Dressing] and laminated four layers [Dura Patch] and five
layers [Surgical Patch and Urogyn Sling]). The manufacturing process will
conform to all internal KNC Quality System regulations as well GMP regulations,
ISO 9001, and EN 46001. In order to accomplish the development of this process
we anticipate the production of seven runs of product (total of **********feet
of intestine). We will continue the work started in Phase 1 to develop final
release criteria and methods for bioburden and LAL testing as well as DSC and
tensile testing. We will also perform all required validations, including
sterilization *, cleaning, process and test method validations. We will utilize
at least 50% of the product from the production runs for development of the
process, appropriate release testing and validations. We anticipate this phase
of the development process will cover six-months.

*    Included in the development quote below is the performance of
     sterilization validations on the ECM product. For the purposes of this
     quotation, we have assumed that we will be performing two sterilization
     validations as we believe the product line will be split into two
     "product families", ******************". This assumption is based on our
     preliminary analysis of the bioburden levels associated with each
     process. We will perform preliminary bioburden testing prior to the
     performance of the sterility validations. Should this preliminary testing
     yield results which allow us to process the product as one product
     family, there will be a cost savings to Organogenesis. We will notify you
     of the results of the preliminary bioburden testing when available. Also
     note that the cost of required regular quarterly dose audits will be
     quoted once we have reached the production phase of the ECM product.

                                  Page 16 of 17

<PAGE>

* CONFIDENDIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                  CONTRACT MANUFACTURING AGREEMENT (continued)
                  ---------------------------------

Phase 2 Highlights:
     .    End result: FULLY VALIDATED, full-scale manufacturing process for
          all four ECM configurations
     .    Approximately *********** hours of KNC manpower
     .    Organogenesis will yield approximately 425 pieces across all
          product configurations. Aside from in-process scrap, testing and
          validations, we will provide additional quantities as available.

The estimated costs for these Phase 2 process development activities will be as
follows:

     Equipment and Custom Fabricated Fixtures **                  ************
     Process Development:
          Manufacturing process development                       ************
          Production runs                                         ************
          Test methods development and execution                  *************
          Validations                                             ************
                                                                  ------------
               Total Phase 2 - Commercial Process Development     *************
                                                                  =============
          **   Equipment and fixtures will remain the property of Kensey Nash
          Corporation to be used in the manufacturing process of the
          Organogenesis ECM product.

The above cost assumes Organogenesis will provide Kensey Nash with all required
(approximately ************* feet) mechanically cleaned porcine intestine for
this development phase. All other materials and all labor, equipment and custom
fabricated fixtures required to complete phase 2 process development are
included in the above cost. The above cost does not include the establishment
and development of currently undefined in-process and lot release tests, nor
does it include the performance of shelf life or packaging integrity studies.
If additional release testing is required or once we have generated enough data
to develop the protocols for the shelf life and/or packaging integrity tests,
we will be happy to quote for these additional services at that time.

Terms:
------
     Invoices will be generated monthly over the six month period in increments
     of *******

Clinical & Regulatory Assistance
Kensey Nash has a full complement of experienced clinical and regulatory
personnel who can assist you with any clinical or regulatory matters upon
request. These services could include the preparation of clinical trial
protocols, regulatory submissions (both US and worldwide), a Device Master File
or any other service you may require during the development phase of this
product. These services would be performed at our hourly consulting rates,
which will be provided upon request.

We are looking forward to working with you and your team on this project. If
you have any questions regarding this quote, please call Russ Kronengold at
(610) 594-4386. To begin the process development work, please call Phyllis
Mahers at (610) 594-4383.

Sincerely,
   /s/

Wendy F. DiCicco                                      Supplier Initials________
Chief Financial Officer                               Buyer Initials___________

                                  Page 17 of 17